Heron Therapeutics, Inc. HRTX
0.36 USD -0.01 (-3.96%)
At closeNov 11, 2026, 7:36 PM EST
0.35 -0.01 -1.92%
After hours · Nov 11, 7:36 PM ET
0.3416 Day range 0.3729
0.26 52-week range 1.58
- YTD
- -72.36%
- 1 year
- -69.03%
News
zacks.com CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
seekingalpha.com Heron Therapeutics, Inc. (HRTX) M&A Call Transcript Heron Therapeutics, Inc. ( HRTX ) M&A Call November 9, 2026 4:30 PM EST Company Participants Joseph Todisco - CEO & Chairman of the Board of Directors Conference Call Participants Daniel Ferry -…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
zacks.com Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.
globenewswire.com Heron Therapeutics Announces Third Quarter 2026 Financial Results CARY, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients…
benzinga.com Heron Therapeutics Q3 EPS $(0.03), Inline, Sales $35.250M Miss $37.500M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.04) per share from the same…
benzinga.com CorMedix To Acquire Heron Therapeutics Assets For $145M Cash, Stock, And Potential Earn-Out Payments Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
globenewswire.com CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
globenewswire.com Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host…
benzinga.com Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement On September 23, 2026 (the "Effective Date"), Heron Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a multi-product Development and License Agreement (the "License
defenseworld.net Head-To-Head Review: Heron Therapeutics (NASDAQ:HRTX) vs. Sol-Gel Technologies (NASDAQ:SLGL) Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Heron Therapeutics (NASDAQ: HRTX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
seekingalpha.com Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
zacks.com Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
marketbeat.com Heron Therapeutics Q2 Earnings Call Highlights Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while…- benzinga.com Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses…
globenewswire.com Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host…
zacks.com New Strong Sell Stocks for July 15th BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
benzinga.com Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.
benzinga.com HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2 HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Heron Therapeutics To Appeal Delaware Court Ruling Invalidating Two CINVANTI Patents In Litigation With Azurity Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a…
globenewswire.com U.S. District Court Issues Decision Regarding CINVANTI® Patents CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
seekingalpha.com Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
marketbeat.com Heron Therapeutics Q1 Earnings Call Highlights Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving…
zacks.com Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall…
zacks.com Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
globenewswire.com Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the…
benzinga.com Earnings Scheduled For May 11, 2026 
zacks.com Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Earnings Breakdown: Heron Therapeutics Q4 - benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com HC Wainwright & Co. Reiterates Buy on Heron Therapeutics, Maintains $6 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $6 price target.- benzinga.com Heron Therapeutics Reports Q4 Preliminary Net Revenue Of ~$40.5M, ~$154.9M For 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.Net…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Heron Therapeutics Includes APONVIE Injectable Emulsion In Guidelines For Postoperative Nausea, Vomiting Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly…
- benzinga.com UPDATE: Heron Therapeutics Q3 Adj. EPS $(0.04) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 166.67 percent. This is a 33.33 percent decrease over losses…
benzinga.com Heron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $156.482M Est Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million to $153.000 million-$163.000 million vs $156.482 million estimate.
benzinga.com Heron Therapeutics Q3 EPS $(0.10) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.01) by 900 percent. This is a 233.33 percent decrease over losses of…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Heron Therapeutics Adopts Section 382 Rights Plan To Protect Nols And Tax Attributes; Plan Approved By Board And Satisfies Covenant Under Note Agreement With Rubric Capital Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights…- benzinga.com Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $3 Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $3.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Heron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $158.538M Est Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million to $153.000 million-$163.000 million vs $158.538 million estimate.